.Attribute Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a mean follow-up of 11 months, patients with metastatic gastrointestinal cysts that received biomarker-matched treatments based on distributing tumor DNA profiling revealed a more significant professional benefit than those receiving unequaled treatment.